These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23877094)

  • 1. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?
    De Groot AS; Einck L; Moise L; Chambers M; Ballantyne J; Malone RW; Ardito M; Martin W
    Hum Vaccin Immunother; 2013 Sep; 9(9):1877-84. PubMed ID: 23877094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agility in adversity: Vaccines on Demand.
    De Groot AS; Moise L; Olive D; Einck L; Martin W
    Expert Rev Vaccines; 2016 Sep; 15(9):1087-91. PubMed ID: 27389971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting biodefense markets.
    Olinger GG
    Hum Vaccin; 2009 Oct; 5(10):660-5. PubMed ID: 19855169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A strategic vaccine facility for the UK.
    Duggan JM; Brooks TJ
    Vaccine; 2005 Mar; 23(17-18):2090-4. PubMed ID: 15755577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Known unknowns and unknown unknowns.
    Burki T
    Lancet Infect Dis; 2018 Apr; 18(4):385-386. PubMed ID: 29582769
    [No Abstract]   [Full Text] [Related]  

  • 6. Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.
    Fan Y; Moon JJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2017 Jan; 9(1):. PubMed ID: 27038091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel vaccine strategies against emerging viruses.
    García-Sastre A; Mena I
    Curr Opin Virol; 2013 Apr; 3(2):210-6. PubMed ID: 23477832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases.
    Terry FE; Moise L; Martin RF; Torres M; Pilotte N; Williams SA; De Groot AS
    Expert Rev Vaccines; 2015 Jan; 14(1):21-35. PubMed ID: 25193104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice.
    Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services
    Fed Regist; 2007 Apr; 72(77):20117-28. PubMed ID: 17520758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
    Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
    Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated BioTherapeutics.
    Aman MJ
    Hum Vaccin Immunother; 2018 Jun; 14(6):1308-1310. PubMed ID: 29641293
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccine provision: Delivering sustained & widespread use.
    Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
    Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical transformation of biodefense vaccines.
    Lu S; Wang S
    Vaccine; 2009 Nov; 27 Suppl 4(0 4):D8-D15. PubMed ID: 19837293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.
    Pezeshki A; Ovsyannikova IG; McKinney BA; Poland GA; Kennedy RB
    Expert Rev Vaccines; 2019 Mar; 18(3):253-267. PubMed ID: 30700167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for emerging pathogens: from research to the clinic. Part two.
    Williamson ED
    Clin Exp Immunol; 2019 Nov; 198(2):141-142. PubMed ID: 31625155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    MacPherson A; Hutchinson N; Schneider O; Oliviero E; Feldhake E; Ouimet C; Sheng J; Awan F; Wang C; Papenburg J; Basta NE; Kimmelman J
    Ann Intern Med; 2021 Mar; 174(3):326-334. PubMed ID: 33226855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools.
    De Groot AS; Moise L; Terry F; Gutierrez AH; Hindocha P; Richard G; Hoft DF; Ross TM; Noe AR; Takahashi Y; Kotraiah V; Silk SE; Nielsen CM; Minassian AM; Ashfield R; Ardito M; Draper SJ; Martin WD
    Front Immunol; 2020; 11():442. PubMed ID: 32318055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging infectious diseases: A proactive approach.
    Bloom DE; Black S; Rappuoli R
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4055-4059. PubMed ID: 28396438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meeting the challenges of medical countermeasure development.
    Maher C; Hu-Primmer J; MacGill T; Courtney B; Borio L
    Microb Biotechnol; 2012 Sep; 5(5):588-93. PubMed ID: 22925432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.